OS Therapies
- Biotech or pharma, therapeutic R&D
OS Therapies is a clinical stage oncology company focused on treatments for osteosarcoma and other solid tumors. OST-HER2, the Company's lead asset, is an immunotherapy leveraging Listeria to trigger a strong immune response targeting the HER2 protein. OST-HER2 has received Rare Pediatric Disease Designation (RPDD) from US FDA and Fast-Track and Orphan Drug designations from US FDA and European Medicines Agency. Positive data for OST-HER in a Phase 2b clinical trial in recurrent, fully resected, lung metastatic osteosarcoma. OS anticipates submitting a BLA to the US FDA in 2025 which, if approved, would trigger a Priority Review Voucher that OS would then sell. OST-HER2 has been conditionally approved by the U.S. Department of Agriculture for the treatment of canines with osteosarcoma.
OS Therapies is advancing its next-generation Antibody Drug Conjugate (ADC) and Drug Conjugates (DC), known as tunable ADC (tADC), which features tunable, tailored antibody-linker-payload candidates.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}